Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period
Breast Care · 2022 · 17 (3) · 264-271
DOI: 10.1159/000519729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Care, online erschienen am 29.10.2021. Verfasst von Alexios Matikas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hellenic Oncology Research Group, Athens, Greece. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), as well as the association between radiologic objective response rate (ORR) and overall survival (OS).
Methods
In this retrospective study, consecutive patients treated for MBC in two centers in Greece from January 1, 1992, to December 31, 2016, were identified and clinicopathologic data regarding tumor characteristics and administered treatments were collected. The efficacy per treatment line in terms of ORR, progression-free survival (PFS) and OS, as well as the prognostic value of ORR at first line were investigated.
Results
A total of 977 patients with MBC were identified; 950 received any treatment. At first line, ORR was 43.5%, PFS 11.4 months (95% CI 10.4–12.4), and median OS 52.4 months (95% CI 47.7–57.1). Lower ORR and shorter PFS were observed with each subsequent line. Median OS was significantly longer for patients that had an objective response at first line, 61.9 months (95% CI 51.1–69.7) for responders versus 41.3 months (95% CI 44.1–63.3) for nonresponders (p < 0.001). In multivariable analysis, failure to achieve an objective response was an independent predictor of poor survival (hazard ratio 1.70, 95% CI 1.34–2.15, p < 0.001).
Conclusion
Late treatment lines for MBC seem to have limited efficacy, while response to first-line therapy is associated with long-term survival. The latter should be considered in the treatment strategy of patients with MBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hellenic Oncology Research Group, Athens, Greece.
Zitieren
APA
Matikas, A., Kotsakis, A., Perraki, M., Hatzidaki, D., Kalbakis, K., Kontopodis, E., Nikolaou, M., & Georgoulias, V. (2022). Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period. Breast Care, 17(3), 264-271. https://doi.org/10.1159/000519729
Vancouver
Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, et al. Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period. Breast Care. 2022;17(3):264-271. doi:10.1159/000519729
BibTeX
@article{Matikas2022,
author = {Matikas, Alexios and Kotsakis, Athanasios and Perraki, Maria and Hatzidaki, Dora and Kalbakis, Konstantinos and Kontopodis, Emmanouil and Nikolaou, Michail and Georgoulias, Vasilios},
title = {Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period},
journal = {Breast Care},
year = {2022},
volume = {17},
number = {3},
pages = {264--271},
doi = {10.1159/000519729}
}
EUVIMED